You are here

clinical trials

Merck’s Keytruda fails in triple negative breast cancer trial

Merck’s Keytruda fails in triple negative breast cancer trial

Pharmaforum

clinical trials

triple negative breast cancer

Flag link:

Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

Yahoo/Zacks.com

Adverum Biotechnologies

clinical trials

wet age-related macular degeneration

Flag link:

FDA and Infant Bacterial Therapeutics agree on the design of Phase III study

FDA and Infant Bacterial Therapeutics agree on the design of Phase III study

CP Wire

Infant Bacterial Therapeutics

necrotizing enterocolitis

clinical trials

Flag link:

Morphosys to take on CAR-Ts in NHL with promising antibody

Morphosys to take on CAR-Ts in NHL with promising antibody

Pharmaforum

non-Hodgkin lymphoma

clinical trials

Flag link:

AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis

AstraZeneca's Fasenra offers severe asthma patients 2 years of benefits: analysis

Fierce Pharma

clinical trials

Flag link:

T3D Therapeutics Receives $9 Million NIH Grant to Advance Alzheimer's Clinical Trial

T3D Therapeutics Receives $9 Million NIH Grant to Advance Alzheimer's Clinical Trial

BioSpace

T3D Therapeutics

Alzheimer's disease

clinical trials

Flag link:

Upcoming events – Phase III data for Chiasma and Novartis

Upcoming events – Phase III data for Chiasma and Novartis

EP Vantage

clinical trials

multiple sclerosis

Flag link:

Actuate raises $22M to expand GSK-3β cancer trial

Actuate raises $22M to expand GSK-3β cancer trial

Fierce Biotech

Acutate Therapeutics

clinical trials

Flag link:

Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication

Agios Pharma's Tibsovo Shows Positive Results in Phase III for Another Cancer Indication

BioSpace

Agios Pharmaceuticals

clinical trials

cholangiocarcinoma

Flag link:

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial

Pfizer’s Abrocitinib yields positive results in phase 3 moderate to severe AD trial

Pharmaceutical Business Review

clinical trials

atopic dermatitis

Flag link:

Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

Allegro announces positive results of ex-US proof-of-concept trial with ALG-1007 for dry eye disease

Pharmaceutical Business Review

clinical trials

dry eye disease

Flag link:

GenSight’s Eye Disease Gene Therapy Shows Sustained Vision Improvement

GenSight’s Eye Disease Gene Therapy Shows Sustained Vision Improvement

BioSpace

Gensight Biologics

clinical trials

Flag link:

FDA tells ImmunoGen to run a second phase 3, sinking stock

FDA tells ImmunoGen to run a second phase 3, sinking stock

Fierce Biotech

mirevtuximab soravtansine

clinical trials

Flag link:

Almost Half of All New Drug Approvals in 2018 Relied on One Clinical Trial

Almost Half of All New Drug Approvals in 2018 Relied on One Clinical Trial

RAPS.org

clinical trials

Flag link:

Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown

Myovant hits goal in uterine fibroid phase 3, teeing up AbbVie showdown

Fierce Biotech

Myovant Sciences

clinical trials

uterine fibroids

Flag link:

Grail, the liquid biopsy startup, picks an approach for its cancer test

Grail, the liquid biopsy startup, picks an approach for its cancer test

Stat

clinical trials

Flag link:

Biotech hits the brakes on their PhIII pivotal for a lead antibiotic as investigators track a high rate of kidney injuries

Biotech hits the brakes on their PhIII pivotal for a lead antibiotic as investigators track a high rate of kidney injuries

Endpoints

clinical trials

nosocomial pneumonia

Flag link:

Getting Clinical On New Drug Launches

Getting Clinical On New Drug Launches

Forbes

clinical trials

Flag link:

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Vifor Pharma’s hypertension and CKD drug Veltassa meets primary endpoint in phase II study

Pharmaceutical Business Review

chronic kidney disease

clinical trials

Flag link:

Philogen who? A low profile but pharma-connected Italian-Swiss hybrid steps out with $68M for a final push over the PhIII finish line

Philogen who? A low profile but pharma-connected Italian-Swiss hybrid steps out with $68M for a final push over the PhIII finish line

Endpoints

clinical trials

Flag link:

Pages